ライフサイエンスコーパス: collagen type II

1 r 2 (DDR2) results from its interaction with collagen type II.

2 ing and expression of the chondrocyte marker collagen type II.

3 not to another arthritis-related Ag, bovine collagen type II.

4 hondrocyte-specific enhancer in the gene for collagen type II.

5 developing cartilage is preceded by that of collagen type II.

6 type II and 12 had IgG binding to denatured collagen type II.

7 ature of IgG binding to native and denatured collagen type II.

8 y immunization with either bovine or chicken collagen type II.

9 mRNA encoding chondrocyte markers including collagen type II, aggrecan, and Pln was elevated in 10T1

10 cartilage specific regulatory element of the Collagen type II alpha 1 (Col2a1) gene.

11 here that the mouse Col2alpha1-Cre promoter (collagen, type II, alpha 1) is active not only in chondr

12 pecific expression of genes, such as Col2a1 (collagen type II alpha1).

13 stimulation of annexin V channel activity by collagen (types II and X) binding can explain how MV are

14 th RA, 12 patients had IgG binding to native collagen type II and 12 had IgG binding to denatured col

15 ly distributed chondrocytes in a matrix with collagen type II and aggrecan and had significantly grea

16 Slug in ATDC5 cells inhibited expression of collagen type II and aggrecan mRNA.

17 re, thickness, density, chondrocyte numbers, collagen type II and aggrecan, and mechanical properties

18 e two major components of the cartilage ECM, collagen type II and aggrecan, as in vivo substrates for

19 cellular matrix, and laminin-alpha1 enhanced collagen type II and reduced collagen type I expression

20 DBA/1 mice were immunised with bovine collagen type II and treated orally with specific CDK9 i

21 We conclude that collagen type-II and CS can be used to promote a more ch

22 ces have been identified in the homotrimeric collagen types II and III, however, it is unclear how VW

23 However, expression of collagen types II and IX was detected largely in the dev

24 of 0.3 M MgCl(2) and immunogold labeling for collagen types II and IX were analyzed by transmission e

25 he mechanism of covalent interaction between collagen types II and IX, we present experimental eviden

26 linated filaggrin, fibrinogen, vimentin, and collagen type II), and studied its effects on arthritic

27 sitive proliferating chondroprogenitors, and collagen type II- and type X-expressing chondrocytes.

28 dules stained intensely with Alcian blue and collagen type II antibodies.

29 markedly increased IgG binding to denatured collagen type II, but not to native collagen.

30 lopment of Abs against ColV and KAT, but not collagen type II (ColII), a cartilaginous protein.

31 lesions and decreased biomarkers of type II collagen (type II collagen neoepitope) and aggrecan (pep

32 en, and type X collagen, but not with type I collagen, type II collagen, or type V collagen.

33 nnective tissue growth factor (CTGF), type I collagen, type II collagen, TGFbeta receptor 1 (TGFbetaR

34 89.8% LacZ(+) cells in peripheral blood and collagen type II costaining with LcZ revealed an average

35 e II fibrillar architecture and indicate the collagen type II cross-link organization, which is cruci

36 /Re) embryos showed high levels of Sox-9 and collagen type II expression and lack of development of h

37 e time, there is restoration of aggrecan and collagen type II expression.

38 hat may add cohesion to a weakened, existing collagen type II fibril network as part of a chondrocyte

39 ce of autoantibodies to native and denatured collagen type II has been reported in some patients with

40 IA was induced in DBA/1 mice by injection of collagen type II in complete Freund adjuvant, and cell s

41 ides and the overall D-periodic structure of collagen type II in native tissues, data that were furth

42 The binding of IgG to denatured collagen type II in the excluded fractions was inhibited

43 -4-transduced DCs inhibited Th1 responses to collagen type II in vitro.

44 ue surrounding the ankle joints of mice with collagen type II-induced arthritis.

45 nts the majority of IgG binding to denatured collagen type II is caused by macromolecular complexes f

46 r chondrocytic markers, such as aggrecan and collagen types II, IX, X, and XI, and by Alcian blue sta

47 , wet weights, wet weight GAG fractions, and collagen type II levels were obtained in bioreactor-grow

48 Inversely, the expression of collagen type II mRNA disappeared during hypertrophic di

49 C-MS/MS assay has been developed to quantify collagen type II neoepitope peptides as biomarkers of co

50 analyses showed that cells produced abundant collagen type-II on type-II scaffolds and collagen type-

51 ering via their beta(1) integrin receptor to collagen type II or chondroadherin was profoundly and ra

52 RTL construct covalently linked with bovine collagen type II peptide (bCII257-270) suitable for use

53 The assay was used to measure the levels of collagen type II peptides in the urine of both clinical

54 patients with RA, the IgG binding to native collagen type II represents true autoantibodies.

55 Opticin colocalizes with the collagen type II-rich fibrillar network of the vitreous,

56 for tissue inhibitor of metalloproteases and collagen type II that are inhibited by IL-1 beta.

57 ed in the oxidation of amine groups and, for collagen type II, the specific decrease in Pyd cross-lin

58 .6 +/- 22.0% of the IgG binding to denatured collagen type II was in the excluded protein fractions.

59 ugh spleen cell proliferation in response to collagen type II was not altered.

60 was shown that a 45-mer peptide fragment of collagen type II with five hydroxyprolines (OH) can be s

61 Immunohistochemical costaining of collagen type II with LacZ and leukocyte defining surfac

62 PRP treated cartilage, with chondromodulin, collagen types II/X downregulated, deiodinase II and net